Comparing Ribociclib versus Palbociclib as a Second Line Treatment in Combination with Fulvestrant in Metastatic Breast Cancer: A Randomised Clinical Trial | Synapse
September 1, 2024Open Access
Comparing Ribociclib versus Palbociclib as a Second Line Treatment in Combination with Fulvestrant in Metastatic Breast Cancer: A Randomised Clinical Trial
Key Points
Key points are not available for this paper at this time.
Abstract
Assessment of CBR, PFS, QOL and toxicity profile of palbociclib and ribociclib.